Literature DB >> 12507412

Pilot trial of albuterol in spinal muscular atrophy.

Michio Hirano.   

Abstract

Entities:  

Year:  2003        PMID： 12507412     DOI： 10.1007/s11910-003-0038-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  7 in total

1.  Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  G S Gronseth; R J Barohn
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

Review 2.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

3.  Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy.

Authors:  J T Kissel; M P McDermott; J R Mendell; W M King; S Pandya; R C Griggs; R Tawil
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

Review 4.  Advances in myasthenia gravis.

Authors:  Emma Ciafaloni; Donald B Sanders
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

5.  Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men.

Authors:  L Martineau; M A Horan; N J Rothwell; R A Little
Journal:  Clin Sci (Lond)       Date:  1992-11       Impact factor: 6.124

6.  De novo and inherited deletions of the 5q13 region in spinal muscular atrophies.

Authors:  J Melki; S Lefebvre; L Burglen; P Burlet; O Clermont; P Millasseau; S Reboullet; B Bénichou; M Zeviani; D Le Paslier
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

7.  A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

Authors:  J Palace; J Newsom-Davis; B Lecky
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910
  7 in total
  1 in total

1.  Successful use of albuterol in a patient with central core disease and mitochondrial dysfunction.

Authors:  L T W Schreuder; M W G Nijhuis-van der Sanden; A de Hair; G Peters; S Wortmann; L A Bok; E Morava
Journal:  J Inherit Metab Dis       Date:  2010-05-05       Impact factor: 4.982
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.